Fulcrum Therapeutics reports Q1 EPS (28c) vs. (43c) last year

“We are pleased with the continued momentum of our lead clinical program, pociredir, in development for the treatment of sickle cell disease, including the recent initiation of the 20 mg dose cohort” said Alex Sapir, Fulcrum’s president and CEO. “The level of engagement that we’ve observed in the PIONEER trial is highly encouraging, with 16 patients enrolled in the 12 mg dose cohort and enrollment underway in the 20 mg dose cohort. We look forward to sharing data from the 12 mg dose cohort in early Q3 2025, and from the 20 mg dose cohort by the end of 2025. We believe that pociredir has the potential to increase fetal hemoglobin to levels that could ameliorate SCD symptomology and transform the standard of care with a once daily oral treatment option.”